a sepanor y Seorpaay ERUUIINST ONNTMI ' r i Kn consol Se see ee " ou Q rau Bo? yy KNMHUAYKU WEHTAP i FOU ne CPEITIE See Bias ee anf ~~~ 44000 eorpan,nacterosa2 — Ol 48 PENYBAMKA CPBMJA eae KAVAMIKA SA VHOEKTMIBHE 1 TPOTICKE BONECTU 111000 Beorpag, Bynesap ocnoGohelsa 16, Ten. 01 1/2683 368, 01 1/2684 071, cbaxc 01/2684 272 MEJIMLIMHCKH @AKYJITET YHHBEP3HTETA Y BEOPPALY Zp CyGomnha 6p. 8 Beorpaa Tlourrosann rocnosune Jlexany. YY nesu Bauer xonuea o npustenu npenapara ivermektin y Bes neversa w npesenunjx COVID-19, 2xen1MO a VeTAKHEMO OcHOBHE CTBApH Koje Cy TPEHYTHO uunIbeHHUe: 1. lek ivermektin je y untbexronornjit 20Gpo nostiar napasirrapHi tek, sj je ynorpeGa Orpaniewta yraaBHoM caMo Ha slevetbe TPOrCKHX apaaitTo3a 2a Koje He NocToje JIpyrH exhukacin npenapari, KOpHeTH ce Hy PeTKHM AepMaTonOUIKHM HH sLHKaLUHjaNa. 2. Hakon HHnuMjaaHor caonuirerba aycTpaajcke rpyne HeTpaxkHBavia a MoxKe HMaTH eexniOwrrapsnt eexar Ha pennuxaunjy SARS-CoV-I9,, in vitro ( wako ce cam neTparkuBa4n orpahyjy Ja je KoHLeHTpaAje sleKa MHOrO Beha Oo” oe Koja ce NpHMeHyje 3a xyMany ynlorpe6y. 3. Kommunie aexa kojy cy norpeOue aa ce nocTure HapeseHia konueHTpayitas1eKa in vitro, je 20 cata npHaterbuBana HH KON JUY/IN, HH KO 2KABOTHIEA. 4. J{o caaa cnponenene kameMuKe cryaHje Koje Henytbanajy Gap mutayM KpurepHiy wa OGjexTHBHOCTH o ebUKACHOCTH H CHTYpHOCTH, HHCY NoKanate e*bitkactoct ivermektina, kako y slevelby TaKo H y npesenunjx COVID-19, Borehe cBeTeKe HHCTHTYUUNje KAO UITO cy (FDA, EMA, $20, CDC), vaya cy sbanMsiia caomurressa H MiIeMa yno2operba, sa ce 8a sek He KOpHCTH y neveHy COVID-19, noweaus of anpra 2020.rosuie, 5. lek ce He Ha1a3H Hi y jesIHOM OGjaBsKeHOM TepannjcKow FTpoToKony G0 Koje 2M sujy cy Mpotokoau jocTynu nperpaxxneaisy, yisbystyjyhit a HaMLy. 6. Y cuery je saGenexeno Buule TOKCHYHHX NocHeAMNA AejcTaBa TeKa. CxoaHo rope HaBesIeHOM, ¥ OBOM TpeHYTKY Ha OcHOBY HajnoysqanMjMX, pemeRaHTHHX nnuhopwannja, ne noctojH onpaszaise 32 NpHMeHY OBO sIeKAKAKO Y sieYeHy. TAKO M Y MpeneMjH COVID-19. Cpnavan nosapan, TIpnator: Hanestene onurre pechepese. Tpod.ap Meana Munouien Fpogp.ap Munous Kqpal ee lees Pykonoansan Kamanxe Tiporp.ap Fopan Crepayponh ‘ Tipog).ap Jovan PatiaD Ivermectin Intended for Animals: Letter to Stakeholders - Do Not Use in Humans as a Treatment for COVID-19. httns://www.fda.gov/safety/medical-product-safety-information/ivermectin- Intended-animals-letter-stakeholders-do-not-use-humans-treatment-covid-19 Popp M, Stegemann M, Metzendorf Mi, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2021 Jul 28;7(7):CD015017. doi: 10.1002/14651858.CD015017.pub2 https://www.ema.europa.eu/en/news/emna-advises-against-use-Ivermectin-prevention- ireatment-covid-19-outside-randomised-clinical-trials WHO therapeutics and COVID-19: living guidelines, v7.1: 9/24/21 iittps://app.m: uideline/nBk« A living WHO guideline on drugs for covid-19. BMJ 2020; 370 dol: https://dol.org/10.1136/bmj.m3379 (Published 04 September 2020) Centers for Disease Control and Prevention. Rapid increase in ivermectin prescri reports of severe illness associated with use of products containing ivermectin to prevent or ‘treat COVID-19. CDC Health Alert Network no. CDCHAN-00449. August 26, 2021 (httosi//emergency.cde.gov/han/2021/han00449.asp). Lind JN, Lovegrove MC, Geller Al, Uyeki TM, Datta SD, Budhnitz DS. Increase in outpatient ivermectin dispensing in the US during the COVID-19 pandemic: a cross-sectional analysis. J Gen untern Med 2021,36:2909-2911, actps:/Awww ecdc.europa.eu/en/covid-19/latest-evidence/treatment